Creating inhibitors that target NBPF1 would involve an in-depth understanding of the protein's structure, the domain responsible for its activity, and the downstream effects of its function. This would necessitate advanced research techniques, including gene expression profiling and protein interaction studies, to elucidate the biological context in which NBPF1 operates. Structural biology tools, such as X-ray crystallography or cryo-electron microscopy, would be employed to visualize the protein at the atomic level, revealing potential binding sites for inhibitor molecules. Moreover, computational modeling could predict how small molecules might interact with these binding sites on NBPF1, providing a starting point for the synthesis of inhibitory compounds.
Once potential inhibitory compounds are identified, they would undergo a rigorous process of optimization and testing. Biochemical assays would be essential to evaluate the binding affinity of these compounds to NBPF1, and to determine the specificity of the interaction to avoid off-target effects. It would be crucial to establish that these compounds can effectively interfere with the function of NBPF1 in a selective and controlled manner. High-throughput screening could be used to test a vast array of compounds for activity against NBPF1, rapidly identifying those with the most promise. Subsequent rounds of chemical modification and optimization would then be guided by the structure-activity relationships discerned from these screening efforts. The optimization process would aim to refine these molecules to enhance their potency and selectivity for NBPF1, while also ensuring they possess suitable properties for further characterization regarding their interaction with the protein and the modulation of its activity. The development of NBPF1 inhibitors would, therefore, be a methodical process, encompassing both the discovery of initial lead compounds and their meticulous refinement to achieve effective modulation of the NBPF1 protein's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor which can alter chromatin structure and gene expression, potentially downregulating NBPF1 transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another histone deacetylase inhibitor, may change the expression pattern of genes by affecting chromatin accessibility. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is a DNA methyltransferase inhibitor that can lead to DNA hypomethylation and potentially upregulate or downregulate gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin binds to GC-rich sequences in DNA, inhibiting transcriptional initiation and possibly affecting NBPF1 expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can modulate various signaling pathways and potentially alter gene expression patterns, though its effect on NBPF1 would need confirmation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus inhibits mTOR signaling, which can result in altered protein synthesis and gene expression, potentially affecting NBPF1. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which can influence cellular metabolism and potentially gene expression, including that of NBPF1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is known to affect the activity of multiple signaling pathways and can modulate gene expression profiles. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide affects the expression of multiple genes by promoting degradation of transcription factors, which may include those regulating NBPF1. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can inhibit nuclear transcription factor kappa-B (NF-kB) which is involved in the expression of various genes. | ||||||